Perspective Therapeutics, Inc. ( CATX ) is down 13% at $11.53 at last check Friday. The downtrend comes as initial results from its study of [212Pb]VMT01 are set to be presented to the International Congress of the Society for Melanoma Research. VMT01 is a MC1R-targeted radiopharmaceutical therapy (RPT) that can be radiolabeled with either 203Pb for patient selection and dosimetry assessments or 212Pb...

On Friday, Capricor Therapeutics ( CAPR ) announced 3-year safety and efficacy results from its ongoing HOPE-2 open-label extension (OLE) study for its lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD). DMD is a genetic disease that causes progressive muscle weakness and degeneration.  Cardiac and orthopedic complications, including scoliosis and contractures (tightened muscles)  The data was highlighted at...

* FAA's audit processes not comprehensive enough, says report * FAA agrees with 16 recommendations to improve oversight * FAA has not enforced timely resolution of undue pressure allegations By David Shepardson WASHINGTON, Oct 11 (Reuters) - A federal watchdog on Friday criticized the Federal Aviation Administration's oversight of Boeing ( BA ) airplane production, saying it does not have...

MILAN (Reuters) - U.S. investment funds are showing confidence in Eni's strategy of spinning off growth businesses in order to attract financial resources, the Italian energy group's CEO Claudio Descalzi said on Friday. Under its so-called 'satellite' strategy, Eni has created several companies dedicated to low-carbon businesses and upstream assets and is currently in talks with U.S. fund KKR to...